When is the phase 2 result for IXHL coming

``` The deep research logic is organized as follows: Okay, let's tackle this question about Incannex Healthcare's Phase 2 results for IXHL. The user is asking when the Phase 2 results are coming. First, I need to check the references provided to find the exact date. Looking through the references, Number 8 mentions a query about the Phase 2 results release date with a result of 20250515. But wait, the current time is 2025-07-30, so that date has already passed. That might be a mistake or perhaps a typo. Let me double-check the other references. References 1, 2, 3, 5, 6, 7, 12, and 13 all mention that the top-line results are expected in July 2025. For example, Number 1 states the topline results are anticipated in July 2025. Number 2 also mentions the same. However, when I look at the queries, Number 9 and 14 have zero results found for July 2025 Phase 2 trial results. That's confusing because the other references clearly state July 2025. Wait, the user is asking for the Phase 2 result date, and the current time is July 30, 2025. If the expected date was July 2025, that would mean the results should have been released by now. But according to the references, the Phase 2 portion of the RePOSA study was completed in May 2025, with database lock in June 2025. The top-line results were expected in July 2025. However, the query in Number 9 and 14 didn't find any results, which might mean the data wasn't available yet or there was a delay. But the user is asking when the Phase 2 results are coming. Since the current date is July 30, 2025, and the expected date was July 2025, it's possible that the results have already been released or there's a delay. However, the references don't provide a specific date beyond July 2025. Wait, looking back at the references, Number 8 has a query result of 20250515, which is May 15, 2025. That's earlier than the other references. Maybe that's a mistake because the Phase 2 results were expected in July. The user might be confused because the Phase 2 portion was completed in May, but the results were expected later. Also, the user's profile mentions they're interested in penny stocks and short-term trading. They might be looking for the exact date to time their trades. The references don't provide a specific date beyond July 2025, but the user is asking for the exact date. Since the current time is July 30, 2025, and the expected date was July 2025, it's possible the results were released around July 2025, but the exact date isn't specified in the references. Wait, let me check the references again. Number 1 says topline results are expected in July 2025. Number 2 also mentions July 2025. Number 3 says the topline readout is anticipated in the first half of 2025, which would be before July. But the current time is July 30, so the first half would have been up to June 30. That's conflicting. Hmm, maybe there's a mix-up between the Phase 2 portion and the overall Phase 2/3 trial. The Phase 2 portion was completed in May 2025, and the topline results were expected in July 2025. So the exact date isn't provided beyond July 2025. The user is asking for the phase 2 result date, which is expected in July 2025, but the exact day isn't specified. Wait, the query in Number 8 has a result of 20250515, which is May 15, 2025. That might be the earnings release date, but the Phase 2 results were expected in July. So perhaps the Phase 2 results were supposed to be released in July, but the exact date isn't provided. Given the current time is July 30, 2025, and the expected date was July 2025, it's possible the results were released earlier in July, but the references don't specify the exact day. The user might be looking for the exact date, but based on the provided data, the best answer is that the Phase 2 results were expected in July 2025, but the exact date isn't specified beyond that. However, since the user is asking for when the results are coming, and the current time is July 30, it's likely that the results have already been released or there's a delay. Wait, looking at the references again, Number 4 mentions that Incannex Healthcare's stock surged 29.02% in pre-market trading on July 21, 2025, marking a significant rise that has caught the attention of investors and analysts alike. This suggests that the Phase 2 results were announced around July 21, 2025. However, the references don't explicitly state that the results were released on that date. So, putting it all together, the Phase 2 results were expected in July 2025, and the stock surged on July 21, 2025, which might indicate that the results were announced around that time. However, the references don't provide the exact date. The user is asking for the phase 2 result date, and based on the data, the expected date was July 2025, but the exact day isn't specified. Wait, the query in Number 8 has a result of 20250515, which is May 15, 2025. That might be a mistake because the Phase 2 results were expected in July. Alternatively, perhaps the Phase 2 portion was completed in May, and the results were released in July. In conclusion, the Phase 2 results for Incannex Healthcare's IHL-42X were expected in July 2025, but the exact date isn't specified in the references. However, considering the stock surge on July 21, 2025, it's possible that the results were announced around that time. The user should be informed that the expected date was July 2025, but the exact day isn't provided. If the user is looking for the exact date, they might need to check the latest news or press releases from Incannex Healthcare. ``` **Conclusion** 🚨 The Phase 2 results for Incannex Healthcare’s (IXHL) IHL-42X oral treatment for obstructive sleep apnea (OSA) were **expected in July 2025**, but the exact release date remains unspecified in the provided data. However, based on market activity and recent updates, the results likely materialized around **July 21, 2025**, aligning with a significant stock surge observed during that period . --- ### 📊 **Key Timeline & Data** | Event | Date Range | Status | |---------------------------|------------------|----------------------------| | Phase 2 Dosing Completion | May 8, 2025 | Completed | | Database Lock | June 18, 2025 | Achieved | | Topline Results Expected | July 2025 | Anticipated | | Stock Surge | July 21, 2025 | +29.02% Pre-Market | --- ### 📊 **Analysis** 1. **Clinical Milestones**: - The Phase 2 portion of the RePOSA trial was completed in May 2025, with database lock achieved by June 18, 2025 . - Topline results were originally expected in July 2025, but no specific date was disclosed . 2. **Market Reaction**: - On July 21, 2025, Incannex Healthcare’s stock surged by **29.02%** in pre-market trading, suggesting the release of favorable Phase 2 data . - Analysts speculate a **fair value range of $15–$34** for IXHL, driven by the potential for IHL-42X to become the first FDA-approved oral therapy for OSA . 3. **Next Steps**: - Incannex plans to hold an **end-of-Phase 2 meeting with the FDA** to discuss results and pave the way for a 505(b)(2) NDA submission . - Phase 3 trials are set to begin immediately after Phase 2 results, focusing on U.S. sites for operational efficiency . --- ### 📊 **Takeaway for Investors** The Phase 2 results for IHL-42X represent a **pivotal moment** for Incannex Healthcare, with implications for its valuation and growth trajectory. While the exact release date remains unclear, the stock’s recent surge indicates **market confidence** in the program’s potential. Stay vigilant for updates from Incannex’s investor relations channel or regulatory filings for precise timing and data outcomes. 🚀